Current Headlines

  1. Trillium Therapeutics Acquires Fluorinov Pharma
    1/28/2016

    FACIT has announced that Trillium Therapeutics Inc. (NASDAQ: TRIL, TSX:TR; "Trillium") has acquired all of the outstanding shares of privately-held Fluorinov Pharma Inc. ("Fluorinov" or the "Company"), a FACIT portfolio company

  2. AbbVie Initiates Enrollment In Phase 3 Clinical Program For Elagolix
    1/28/2016

    AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the initiation of the first of two planned Phase 3 clinical studies evaluating the safety and efficacy of Elagolix alone or in combination with add-back therapy compared to placebo

  3. Stemedica Announces Completion Of Enrollment Trial For Ischemic Stroke
    1/27/2016

    Stemedica Cell Technologies, Inc. announced completion of enrollment into "A Phase I/IIa, Multi-Center, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects with Ischemic Stroke."

  4. MetaCure Announces Appointment Of New CEO
    1/27/2016

    MetaCure has announced the appointment of Adrian Gilmore as CEO.

  5. Astellas Extends Offer To Acquire Outstanding Shares Of Ocata Therapeutics
    1/22/2016

    Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO:Paul Wotton, "Ocata") today announced that Astellas has extended, through its indirect wholly-owned subsidiary Laurel Acquisition Inc., the offering period of the tender offer to purchase all issued and outstanding shares of common stock of Ocata for a price of US$8.50 per share, net to the holder in cash ("Tender Offer") until 5:00 pm, U.S. Eastern Time, on February 9, 2016.

  6. Shire Completes Acquisition Of Dyax
    1/22/2016

    Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that it has completed its acquisition of Dyax Corp. (NASDAQ: DYAX) in an all-cash transaction valued at approximately $5.9 billion, comprised of $37.30 in cash per Dyax share.

  7. Asterias Biotherapeutics Announces Completion Of Transfer Of AST-VAC2 Manufacturing Process
    1/21/2016

    Asterias Biotherapeutics, Inc. (NYSE MKT: AST), announced that it has completed the transfer of its manufacturing processes to produce AST-VAC2 to Cancer Research UK.

  8. BioCision To Discuss "Last Mile" Challenges Cell & Gene Therapy World 2016
    1/20/2016

    BioCision, LLC, recently announced they will host a panel discussion at Phacilitate’s Cell and Gene Therapy World 2016 conference in Washington, DC.

  9. Biovest Spins Off Cell Culture Company To Focus On Bioreactors And BioService
    1/20/2016

    Biovest International Inc. announced that it will spin off its instrument and contract manufacturing offerings into a single wholly-owned subsidiary named “Cell Culture Company, LLC.” Cell Culture Company will supply automated single-use perfusion bioreactor systems and custom mammalian cell and protein manufacturing services to the diagnostic, therapeutic, and animal healthcare industries.

  10. Biovest International Spins Off Cell Culture Company To Focus On Bioreactors And BioService Solutions
    1/20/2016

    Biovest International Inc. announced that it will spin off its instrument and contract manufacturing offerings into a single wholly-owned subsidiary named “Cell Culture Company, LLC.”